Aging News and Research

RSS

Large B-cell non-Hodgkin's lymphoma now treatable

Cases of non-Hodgkin lymphoma have more than tripled in the last thirty years according to the latest Cancer Research UK figures published today.

8 Sep 2009

Oxidative DNA damage: Primary cause of mutation

A study that tracked genetic mutations through the human equivalent of about 5,000 years has demonstrated for the first time that oxidative DNA damage is a primary cause of the process of mutation - the fuel for evolution but also a leading cause of aging, cancer and other diseases.

8 Sep 2009

Early schizophrenia symptoms include unusually high CA1 subfield activity

In the first functional magnetic resonance imaging (fMRI) study of its kind, neurologists and psychiatrists at Columbia University have identified an area of the brain involved in the earliest stages of schizophrenia and related psychotic disorders.

7 Sep 2009

CIHR funds for Alzheimer's and stroke research

The Canadian Institutes of Health Research (CIHR) has announced a grant totaling more than a million dollars for John F. MacDonald's research on Alzheimer's disease.

7 Sep 2009

Cancer drug could restore memory deficits in Alzheimer's patients

A drug now used to treat cancer may also be able to restore memory deficits in patients with Alzheimer's disease, according to a new study conducted by scientists at Columbia University Medical Center, which appeared in the September issue of The Journal of Alzheimer's Disease: Volume 18:1.

7 Sep 2009

$2.4M approved for LHIN's Urgent Priorities and Aging at Home initiatives

At its meeting on August 26 2009, the South West LHIN Board approved a total of $2.4M for 2009/10 in one-time and base funding as part of its Urgent Priorities and Aging at Home initiatives. These initiatives and projects support the priorities identified in the LHIN's Integrated Health Service Plan (IHSP) and will help to address health care pressures within the South West LHIN.

5 Sep 2009

Alzheimer’s disease researcher joins UBC's European Scientific Advisory Board

United BioSource Corporation (UBC) announced this summer at ICAD 2009 that Bengt Winblad, MD, PhD has joined its European Scientific Advisory Board for CNS Clinical Trials. Professor Winblad is one of the world’s leading Alzheimer’s disease researchers and currently serves as Professor of Geriatric Medicine and Chief Physician at the Karolinska University Hospital, Huddinge, and the Karolinska Institute in Stockholm, Sweden.

5 Sep 2009

Clinical trial of Cerebroprotein Hydrolysate for Injection completes

Hard to Treat Diseases (the "Company") announced today, that its China based subsidiary Mellow Hope, has just finished (August 2009) the clinical trial of Cerebroprotein Hydrolysate for Injection (Brand name: NUTRIPROTEIN) in India.

5 Sep 2009

HTDS announces closure of Regulation D 504 offering

Hard to Treat Diseases (the "Company") (HTDS.PK) announced today that it has closed its Regulation D, Rule 504 offering and is no longer selling shares of its common stock to accredited investors.

4 Sep 2009

Grant application guidelines released by The Center for Technology and Aging

The Center for Technology and Aging today released grant application guidelines for a $500,000 Medication Optimization Diffusion Grants Program. Up to six one-year grants will be made to organizations successfully proposing programs that directly benefit older adults. Four or five grants will focus on Californians, while one or two may benefit older adults in other regions of the U.S.

4 Sep 2009

ROS in cells contributes to aging

With all the hype about beneficial antioxidants in everything from face cream to cereal bars, you'd think their targets---oxygen radicals---must be up to no good. It's true, the buildup of oxygen radicals and other reactive oxygen species (ROS) in cells contributes to aging and possibly to diseases such as cancer and Alzheimer's.

3 Sep 2009

Optimized turmeric extracts may prevent memory loss

scientists with HerbalScience Group LLC, working with researchers from other organizations and medical institutions, conducted an in-depth study of optimized turmeric extracts, demonstrating that key bioactives in the botanical extracts inhibit aggregation and release of amyloid, a protein fragment considered a prime causal suspect in Alzheimer's disease.

3 Sep 2009

Reliable and relevant information needed to rein in the costs of federal health-care programs, says study

For economists and policy-makers to understand the true value of the costs and savings of preventive health programs for chronic disease, the Congressional Budget Office (CBO) should incorporate long-term clinical outcomes data and look beyond the 10-year window when making cost estimates, says a team of University of Chicago researchers in today's issue of Health Affairs.

3 Sep 2009

Consumers seek functional foods and supplements to enhance wellness quotient

An expanding aging population and increased consumer awareness boosts growth for the U.S. bone and joint health ingredients market. Consumers increasingly seek supplements and functional foods that enhance their wellness quotient and have strong scientific backup.

3 Sep 2009

Atrium Innovations supports Wobenzym(R) brand development in Germany

Atrium Innovations Inc. (TSX: ATB), a leading developer, manufacturer and marketer of science-based and professionally supported products for the Health and Nutrition industry, today announced various initiatives to support the development of its Wobenzym(R) brand in Germany.

3 Sep 2009

THNN's Vice President to supervise the clinical research applications of SUPER MEAL RX

THNN Inc. (Transformation Health Nutrition Naturals Inc.) enthusiastically announces the appointment of Dr. Thoger Malmstrom to the position of Vice President for Nutritional Wellness Applications.

3 Sep 2009

Report on ageing world inspires employers to expand and shift their strategic thinking, says Chairman of Mercer

The World Economic Forum has just published Transforming Pensions and Healthcare in a Rapidly Ageing World: Opportunities and Collaboration Strategies with the support of Mercer and the OECD (Organisation for Economic Cooperation and Development). The report and a related Mercer Perspective can be downloaded at www.mercer.com/WEF.

3 Sep 2009

New probe for identifying chemical process affected proteins functions like GPS

Scientists in Michigan are reporting the development of a powerful new probe for identifying proteins affected by a key chemical process important in aging and disease. The probe works like a GPS or navigation system for finding these proteins in cells. It could lead to new insights into disease processes and identify new targets for disease treatments, the researchers say. Their study is scheduled for the Sept. 18 issue of ACS Chemical Biology, a monthly journal.

3 Sep 2009

New Marketing Authorization Application for Rhucin submitted to the EMEA by Pharming

Biotech company Pharming Group NV ("Pharming" or "the Company") (NYSE Euronext: PHARM) today announced that it has submitted the Marketing Authorization Application (MAA) for Rhucin for the treatment of acute attacks of Hereditary Angioedema (HAE) to the European Medicines Agency (EMEA).

3 Sep 2009

Phase 1 single dose clinical trial of Acceleron Pharma's ACE-031 increases lean body mass

Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of cells and tissues including red blood cells, bone, and muscle, today announced preliminary results from the ACE-031 Phase 1 single dose clinical trial indicating that ACE-031 was safe and well-tolerated at all dose levels and increased lean body mass.

2 Sep 2009